The long-awaited US launch of Medtronic’s Symplicity renal denervation system for treating drug-resistant hypertension will be delayed another year, the company explained in a 15 October filing with the Securities and Exchange Commission.
Medtronic now estimates that it will be able to file a premarket approval application for Symplicity in the second half...







